CD200 expression in plasma cells of nonmyeloma immunoproliferative disorders: Clinicopathologic features and comparison with plasma cell myeloma

American Journal of Clinical Pathology

Volumn 138, Issue 6, 2012, Pages 867-876

  Olteanu, Horatiu ^a   Harrington, Alexandra M ^a   Kroft, Steven H ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

CD200; Flow cytometry; Immunophenotype; Lymphoplasmacytic lymphoma; MGUS

Indexed keywords

CD200 ANTIGEN;

ADULT; AGED; ARTICLE; BONE MARROW BIOPSY; FEMALE; FLOW CYTOMETRY; HUMAN; IMMUNOPHENOTYPING; LYMPHOPROLIFERATIVE DISEASE; MAJOR CLINICAL STUDY; MALE; MONOCLONAL IMMUNOGLOBULINEMIA; MULTIPLE MYELOMA; NONMYELOMA IMMUNOPROLIFERATIVE DISORDER; PLASMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; WALDENSTROEM MACROGLOBULINEMIA;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD; BONE MARROW; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOPHENOTYPING; IMMUNOPROLIFERATIVE DISORDERS; MALE; MIDDLE AGED; MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE; MULTIPLE MYELOMA; PLASMA CELLS; WALDENSTROM MACROGLOBULINEMIA;

EID: 84869234870     PISSN: 00029173     EISSN: 19437722     Source Type: Journal    
DOI: 10.1309/AJCP3TQR1TFHHGAS     Document Type: Article

References (40)

1. Barclay AN, Wright GJ, Brooke G, et al. CD200 and membrane protein interactions in the control of myeloid cells. Trends Immunol. 2002;23:285-290. (Pubitemid 34628770)
2. Kawasaki BT, Farrar WL. Cancer stem cells, CD200 and immunoevasion. Trends Immunol. 2008;29:464-468.
3. Gorczynski RM. CD200 and its receptors as targets for immunoregulation. Curr Opin Invest Drugs. 2005;6:483-488. (Pubitemid 40613969)
4. Gorczynski RM, Chen Z, Hu J, et al. Evidence of a role for CD200 in regulation of immune rejection of leukaemic tumour cells in C57BL/6 mice. Clin Exp Immunol. 2001;126:220-229. (Pubitemid 32995135)
5. Siva A, Xin H, Qin F, et al. Immune modulation by melanoma and ovarian tumor cells through expression of the immunosuppressive molecule CD200. Cancer Immunol Immunother. 2008;57:987-996.
6. Tonks A, Pearn L, Musson M, et al. Transcriptional dysregulation mediated by RUNX1-RUNX1T1 in normal human progenitor cells and in acute myeloid leukaemia. Leukemia. 2007;21:2495-2505. (Pubitemid 350148893)
7. Coustan-Smith E, Song G, Clark C, et al. New markers for minimal residual disease detection in acute lymphoblastic leukemia. Blood. 2011;117:6267-6276.
8. Brunetti L, Di Noto R, Abate G, et al. CD200/OX2, a cell surface molecule with immuno-regulatory function, is consistently expressed on hairy cell leukaemia neoplastic cells. Br J Haematol. 2009;145:665-667.
9. McWhirter JR, Kretz-Rommel A, Saven A, et al. Antibodies selected from combinatorial libraries block a tumor antigen that plays a key role in immunomodulation. Proc Natl Acad Sci U S A. 2006;103:1041-1046. (Pubitemid 43212218)
10. Dorfman DM, Shahsafaei A. CD200 (OX-2 membrane glycoprotein) expression in B cell-derived neoplasms. Am J Clin Pathol. 2010;134:726-733.
11. Dorfman DM, Shahsafaei A. CD200 (OX-2 membrane glycoprotein) is expressed by follicular T helper cells and in angioimmunoblastic T-cell lymphoma. Am J Surg Pathol. 2011;35:76-83.
12. Alapat D, Coviello-Malle J, Owens R, et al. Diagnostic usefulness and prognostic impact of CD200 expression in lymphoid malignancies and plasma cell myeloma. Am J Clin Pathol. 2012;137:93-100.
13. Moreaux J, Hose D, Reme T, et al. CD200 is a new prognostic factor in multiple myeloma. Blood. 2006;108:4194-4197. (Pubitemid 44913292)
14. Olteanu H, Harrington AM, Hari P, et al. CD200 expression in plasma cell myeloma. Br J Haematol. 2011;153:408-411.
15. Cannizzo E, Bellio E, Sohani AR, et al. Multiparameter immunophenotyping by flow cytometry in multiple myeloma: the diagnostic utility of defining ranges of normal antigenic expression in comparison to histology. Cytometry B Clin Cytom. 2010;78:231-238.
16. Rawstron AC, Orfao A, Beksac M, et al. Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders. Haematologica. 2008;93:431-438. (Pubitemid 351398645)
17. Paiva B, Almeida J, Perez-Andres M, et al. Utility of flow cytometry immunophenotyping in multiple myeloma and other clonal plasma cell-related disorders. Cytometry B Clin Cytom. 2010;78:239-252.
18. Raja KR, Kovarova L, Hajek R. Review of phenotypic markers used in flow cytometric analysis of MGUS and MM, and applicability of flow cytometry in other plasma cell disorders. Br J Haematol. 2010;149:334-351.
19. Frebet E, Abraham J, Genevieve F, et al. A GEIL flow cytometry consensus proposal for quantification of plasma cells: application to differential diagnosis between MGUS and myeloma. Cytometry B Clin Cytom. 2011;80:176-185.
20. Yuan CM, Stetler-Stevenson M. Role of flow cytometry of peripheral blood and bone marrow aspirates in early myeloma. Semin Hematol. 2011;48:32-38.
21. Kumar S, Kimlinger T, Morice W. Immunophenotyping in multiple myeloma and related plasma cell disorders. Best Pract Res Clin Haematol. 2010;23:433-451.
22. Group IMW. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol. 2003;121:749-757.
23. Rajkumar SV. MGUS and smoldering multiple myeloma: update on pathogenesis, natural history, and management. Hematology Am Soc Hematol Educ Program. 2005:340-345.
24. Ocqueteau M, Orfao A, Almeida J, et al. Immunophenotypic characterization of plasma cells from monoclonal gammopathy of undetermined significance patients. Implications for the differential diagnosis between MGUS and multiple myeloma. Am J Pathol. 1998;152:1655-1665. (Pubitemid 28275024)
25. Olteanu H, Wang HY, Chen W, et al. Immunophenotypic studies of monoclonal gammopathy of undetermined significance. BMC Clin Pathol. 2008;8:13.
26. Perez-Persona E, Vidriales MB, Mateo G, et al. New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells. Blood. 2007;110:2586-2592. (Pubitemid 47523182)
27. Perez-Persona E, Mateo G, Garcia-Sanz R, et al. Risk of progression in smouldering myeloma and monoclonal gammopathies of unknown significance: comparative analysis of the evolution of monoclonal component and multiparameter flow cytometry of bone marrow plasma cells. Br J Haematol. 2009;148:110-114.
28. Morice WG, Chen D, Kurtin PJ, et al. Novel immunophenotypic features of marrow lymphoplasmacytic lymphoma and correlation with Waldenstrom's macroglobulinemia. Mod Pathol. 2009;22:807-816.
29. San Miguel JF, Vidriales MB, Ocio E, et al. Immunophenotypic analysis of Waldenstrom's macroglobulinemia. Semin Oncol. 2003;30:187-195. (Pubitemid 36506307)
30. Konoplev S, Medeiros LJ, Bueso-Ramos CE, et al. Immunophenotypic profile of lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia. Am J Clin Pathol. 2005;124:414-420. (Pubitemid 41232928)
31. McKenna RW, Kyle RA, Kuehl WM, et al. Plasma cell neoplasms. In: Swerdlow SH, Campo E, Harris NL, et al, eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2008:200-213.
32. Swerdlow SH, Berger F, Pileri SA, et al. Lymphoplasmacytic lymphoma. In: Swerdlow SH, Campo E, Harris NL, et al, eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2008:194-195.
33. Spears MD, Olteanu H, Kroft SH, et al. The immunophenotypic stability of plasma cell myeloma by flow cytometry. Int J Lab Hematol. 2011;33:483-491.
34. Heerema NA, Raimondi SC, Anderson JR, et al. Specific extra chromosomes occur in a modal number dependent pattern in pediatric acute lymphoblastic leukemia. Genes Chromosomes Cancer. 2007;46:684-693. (Pubitemid 46802336)
35. Rajkumar SV, Kyle RA, Therneau TM, et al. Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance. Blood. 2005;106:812-817. (Pubitemid 41076419)
36. Kyle RA, Durie BG, Rajkumar SV, et al. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management. Leukemia. 2010;24:1121-1127.
37. Smock KJ, Perkins SL, Bahler DW. Quantitation of plasma cells in bone marrow aspirates by flow cytometric analysis compared with morphologic assessment. Arch Pathol Lab Med. 2007;131:951-955. (Pubitemid 46906389)
38. Lopez-Corral L, Gutierrez NC, Vidriales MB, et al. The progression from MGUS to smoldering myeloma and eventually to multiple myeloma involves a clonal expansion of genetically abnormal plasma cells. Clin Cancer Res. 2011;17:1692-1700.
39. Bacher U, Haferlach T, Kern W, et al. Correlation of cytomorphology, immunophenotyping, and interphase fluorescence in situ hybridization in 381 patients with monoclonal gammopathy of undetermined significance and 301 patients with plasma cell myeloma. Cancer Genet Cytogenet. 2010;203:169-175.
40. Pillai V, Pozdnyakova O, Charest K, et al. Flow cytometric assessment of CD200 (OX-2 membrane glycoprotein) expression in B cell lymphoproliferative disorder [abstract]. Presented at the United States and Canadian Academy of Pathology 101st Annual Meeting; Vancouver, Canada; March 20, 2012.